Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients

• Status: Recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

18F-labeled prostate-specific membrane antigen (PSMA) ligand-positron emission tomography (PET) offers advantages over 68Ga-labeled PSMA ligands. Al18F-PSMA-617 is a novel 18F-PSMA compound used for prostate cancer (PCa) imaging. This pilot study was prospectively designed to compare the lesion detectability of Al18F-PSMA-617 and related 68Ga-PSMA-617 PET/CT in patients with PCa

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Treatments: Gallium 68 PSMA-11

Criteria

Inclusion Criteria:

• confirmed untreated prostate cancer patients;

• 68Ga-PSMA617 and Al18F-PSMA-617 PET/CT within two consecutive days;

• signed written consent.

Exclusion Criteria:

• known allergy against PSMA; • any medical condition that in the opinion of the investigator may significantly interfere with study compliance.